Therapy News and Research

RSS

Hospitals find new ways to serve growing senior, immigrant, suburban populations

News outlets report on hospital industries in Houston, Texas; Irvine, Calif. and Madison County, La.

9 Sep 2010

Micro-RNAs programmed cells can lead to malignant growth

Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.

9 Sep 2010

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Competitive Technologies, Inc. announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare® Pain Therapy Treatment

9 Sep 2010

NIH awards second $8 million grant for research into health effects of botanical estrogens

An ongoing research initiative into the health effects of botanical estrogens will get an $8 million boost from the National Institutes of Health.

9 Sep 2010

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream. A new study involving 195 infants in South Africa found that children who were treated with PI and then switched to nevirapine were more likely to maintain virus below the detection threshold of the test than infants who continued to receive PI.

9 Sep 2010

Ohio State University receives five-year grant to improve drug therapy using gene profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

9 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Clinical trials in a variety of areas within interventional cardiovascular medicine that will be presented at TCT 2010 will directly affect the way that people with cardiovascular disease are treated. Breakthroughs in science and medical research, presented exclusively at TCT, will lead to new treatments that are minimally invasive and involve shorter recovery times. Among the topics being covered are stenting in the femoral artery, polymer-free drug-eluting stents, valves and drug-eluting balloons used in angioplasty.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

NIH announces $161.3 million for expansion of Pharmacogenomics Research Network

The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network (PGRN), a nationwide collaborative of scientists focused on understanding how genes affect a person's response to medicines.

8 Sep 2010

ECNP honors Kaj Blennow with 2010 Neuropsychopharmacology Award

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Kaj Blennow as the recipient of the 2010 ECNP Neuropsychopharmacology Award in recognition of his original and influential contributions to Alzheimer's disease research. The ECNP Neuropsychopharmacology Award is presented annually and recognises distinguished research in neuropsychopharmacology and closely related disciplines. The award is accompanied by a prize of - 20,000.

8 Sep 2010

Scientists gather to present research findings at ASHG 2010 Meeting

The world's top scientists and clinicians in the human genetics field will gather in Washington, D.C., to present their latest research findings at the 60th Annual Meeting of the American Society of Human Genetics, from Tuesday, November 2, through Saturday, November 6, 2010, at the Walter E. Washington Convention Center in D.C.

8 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

TransOral Robotic Surgery removes head and neck cancer tumors, while preserving speech

An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.

8 Sep 2010

Researchers investigate brain network to understand mind disorders

Uncovering the secrets of the brain requires an intense network of collaborative research. Building on a tool that was co-developed in his laboratory and described in a recent issue of Brain, Dr. Yaniv Assaf of Tel Aviv University's Department of Neurobiology is collaborating with an international team of scientists to understand how different parts of the human brain "connect" and to turn this information into a "brain atlas."

8 Sep 2010

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

HIV infected children in South Africa who were exposed to the drug nevirapine at birth (used to help prevent mother to child HIV transmission) and then received a protease inhibitor (PI) for viral suppression achieved lower rates of viremia (virus in the blood stream) if they were switched to nevirapine, compared to children who continued on the PI-based regimen, according to a study in the September 8 issue of JAMA.

8 Sep 2010

San Antonio podiatrist offers new MLS Therapy for pain management

Dr. Ed Davis, a podiatrist with offices in San Antonio, TX and Live Oak, TX, announces the immediate offering of a new form of laser therapy to patients in the San Antonio area. The addition is part of Dr. Davis' continued investment in advanced technologies and progressive procedures.

8 Sep 2010

Study finds non-hormonal therapies can relieve hot flashes in women with breast cancer

Many women enduring hot flashes experience the heat, sweat and reddened upper body as an uncomfortable inconvenience. However, hot flashes can greatly diminish a woman's quality of life, disrupting sleep at night or causing embarrassment as she goes about her daily business. Many women enduring hot flashes experience the heat, sweat and reddened upper body as an uncomfortable inconvenience. However, hot flashes can greatly diminish a woman's quality of life, disrupting sleep at night or causing embarrassment as she goes about her daily business.

8 Sep 2010

Therapy News and Research

Hospitals find new ways to serve growing senior, immigrant, suburban populations

Micro-RNAs programmed cells can lead to malignant growth

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

NIH awards second $8 million grant for research into health effects of botanical estrogens

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Ohio State University receives five-year grant to improve drug therapy using gene profiles

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

NIH announces $161.3 million for expansion of Pharmacogenomics Research Network

ECNP honors Kaj Blennow with 2010 Neuropsychopharmacology Award

Scientists gather to present research findings at ASHG 2010 Meeting

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

TransOral Robotic Surgery removes head and neck cancer tumors, while preserving speech

Researchers investigate brain network to understand mind disorders

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

San Antonio podiatrist offers new MLS Therapy for pain management

Study finds non-hormonal therapies can relieve hot flashes in women with breast cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News